Roche to Share New Data on Elecsys Alzheimer’s Blood Tests at AAIC

Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer's Biomarker Profiling

Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer’s disease detection and staging

Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling

Fremont, CA, July 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced that its NULISA™ platform will be featured in more than 140 poster…

Roche to Share New Data on Elecsys Alzheimer’s Blood Tests at AAIC

Presentations will evaluate the performance of the company’s pTau217 and pTau181 assays while also highlighting phase 3 clinical research for the investigational therapy trontinemab for Alzheimer’s disease. Roche announced it will present 18 oral and poster presentations from its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference (AAIC) 2026 in London from July 12-15. The data focus on the development of diagno…